| Loretta Jane Scism, MD | |
|
784 E Main St, Lancaster, OH 43130-3983 | |
| (740) 654-4942 | |
| Not Available |
| Full Name | Loretta Jane Scism |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 20 Years |
| Location | 784 E Main St, Lancaster, Ohio |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1336346865 | NPI | - | NPPES |
| 000000529137 | Other | OH | ANTHEM |
| 00002803653 | Other | OH | UHC |
| 2764923 | Medicaid | OH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 35-090075 (Ohio) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Riverside Methodist Hospital | Columbus, OH | Hospital |
| Hocking Valley Community Hospital | Logan, OH | Hospital |
| Fairfield Medical Center | Lancaster, OH | Hospital |
| Grant Medical Center | Columbus, OH | Hospital |
| Ohiohealth O'bleness Hospital | Athens, OH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Ohiohealth Corporation | 6305758426 | 1900 |
News Archive
UCB announced today that the European Commission (EC) has approved Vimpat (lacosamide) as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older. Vimpat is the first new antiepileptic drug (AED) for partial-onset seizures in three years and offers a new treatment option for European patients living with uncontrolled partial-onset epilepsy.
Driving Miranda, a protein in fruit flies crucial to switch a stem cell's fate, is not as complex as biologists thought, according to University of Oregon biochemists. They've found that one enzyme (aPKC) stands alone and acts as a traffic cop that directs which roads daughter cells will take.
InNexus Biotechnology Inc. has announced the United States Food & Drug Administration (FDA) has completed its comprehensive review of the development plans for InNexus' lead preclinical candidate, DXL625 (CD20) for the prospective treatment of Non-Hodgkin's Lymphoma (NHL) and/or Chronic Lymphocytic Leukemia (CLL).
The antibiotic used to treat trachoma, "the world's leading preventable cause of blindness," may also protect children living in Ethiopia from death from of other diseases, according to a recent study, the Associated Press reports.
Doxycycline alone is more effective against the most common form of filariasis in Southeast Asia than the standard treatment, with significantly fewer side effects, according to a new study published in the May 1 issue of Clinical Infectious Diseases and currently available online.
› Verified 5 days ago
| Entity Name | Ohiohealth Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578545273 PECOS PAC ID: 6305758426 Enrollment ID: O20031105000532 |
News Archive
UCB announced today that the European Commission (EC) has approved Vimpat (lacosamide) as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older. Vimpat is the first new antiepileptic drug (AED) for partial-onset seizures in three years and offers a new treatment option for European patients living with uncontrolled partial-onset epilepsy.
Driving Miranda, a protein in fruit flies crucial to switch a stem cell's fate, is not as complex as biologists thought, according to University of Oregon biochemists. They've found that one enzyme (aPKC) stands alone and acts as a traffic cop that directs which roads daughter cells will take.
InNexus Biotechnology Inc. has announced the United States Food & Drug Administration (FDA) has completed its comprehensive review of the development plans for InNexus' lead preclinical candidate, DXL625 (CD20) for the prospective treatment of Non-Hodgkin's Lymphoma (NHL) and/or Chronic Lymphocytic Leukemia (CLL).
The antibiotic used to treat trachoma, "the world's leading preventable cause of blindness," may also protect children living in Ethiopia from death from of other diseases, according to a recent study, the Associated Press reports.
Doxycycline alone is more effective against the most common form of filariasis in Southeast Asia than the standard treatment, with significantly fewer side effects, according to a new study published in the May 1 issue of Clinical Infectious Diseases and currently available online.
› Verified 5 days ago
| Entity Name | Athens Medical Associates, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1982714358 PECOS PAC ID: 9537112685 Enrollment ID: O20050301000331 |
News Archive
UCB announced today that the European Commission (EC) has approved Vimpat (lacosamide) as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older. Vimpat is the first new antiepileptic drug (AED) for partial-onset seizures in three years and offers a new treatment option for European patients living with uncontrolled partial-onset epilepsy.
Driving Miranda, a protein in fruit flies crucial to switch a stem cell's fate, is not as complex as biologists thought, according to University of Oregon biochemists. They've found that one enzyme (aPKC) stands alone and acts as a traffic cop that directs which roads daughter cells will take.
InNexus Biotechnology Inc. has announced the United States Food & Drug Administration (FDA) has completed its comprehensive review of the development plans for InNexus' lead preclinical candidate, DXL625 (CD20) for the prospective treatment of Non-Hodgkin's Lymphoma (NHL) and/or Chronic Lymphocytic Leukemia (CLL).
The antibiotic used to treat trachoma, "the world's leading preventable cause of blindness," may also protect children living in Ethiopia from death from of other diseases, according to a recent study, the Associated Press reports.
Doxycycline alone is more effective against the most common form of filariasis in Southeast Asia than the standard treatment, with significantly fewer side effects, according to a new study published in the May 1 issue of Clinical Infectious Diseases and currently available online.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Loretta Jane Scism, MD 5450 Frantz Rd Ste 360, Dublin, OH 43016-4141 Ph: () - | Loretta Jane Scism, MD 784 E Main St, Lancaster, OH 43130-3983 Ph: (740) 654-4942 |
News Archive
UCB announced today that the European Commission (EC) has approved Vimpat (lacosamide) as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older. Vimpat is the first new antiepileptic drug (AED) for partial-onset seizures in three years and offers a new treatment option for European patients living with uncontrolled partial-onset epilepsy.
Driving Miranda, a protein in fruit flies crucial to switch a stem cell's fate, is not as complex as biologists thought, according to University of Oregon biochemists. They've found that one enzyme (aPKC) stands alone and acts as a traffic cop that directs which roads daughter cells will take.
InNexus Biotechnology Inc. has announced the United States Food & Drug Administration (FDA) has completed its comprehensive review of the development plans for InNexus' lead preclinical candidate, DXL625 (CD20) for the prospective treatment of Non-Hodgkin's Lymphoma (NHL) and/or Chronic Lymphocytic Leukemia (CLL).
The antibiotic used to treat trachoma, "the world's leading preventable cause of blindness," may also protect children living in Ethiopia from death from of other diseases, according to a recent study, the Associated Press reports.
Doxycycline alone is more effective against the most common form of filariasis in Southeast Asia than the standard treatment, with significantly fewer side effects, according to a new study published in the May 1 issue of Clinical Infectious Diseases and currently available online.
› Verified 5 days ago
Dr. Scott Burdine Hahn, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1800 Granville Pike, Lancaster, OH 43130 Phone: 740-785-4678 Fax: 614-392-4636 | |
Jeffrey M Ayers, D.O. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1155 E Main St, Lancaster, OH 43130 Phone: 740-689-6758 Fax: 740-689-6759 | |
Brian Robert Jenkins, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 1703 N Memorial Dr, Lancaster, OH 43130 Phone: 740-653-6145 Fax: 740-653-6250 | |
Richard B. Sielski, M.D, Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2405 N Columbus St, Suite 200, Lancaster, OH 43130 Phone: 740-687-0303 Fax: 740-687-5898 | |
Joseph M Ginty, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1800 Granville Pike, Lancaster, OH 43130 Phone: 740-785-4678 Fax: 740-687-1518 | |
Theresa A. Dyar, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2405 N Columbus St Ste 200, Lancaster, OH 43130 Phone: 740-689-3627 Fax: 740-687-5898 | |
Dr. Bradley Jonathan Lewis, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1147 E Main St, Lancaster, OH 43130 Phone: 740-687-9173 Fax: 740-689-3740 |